0001572426-17-000028.txt : 20170802 0001572426-17-000028.hdr.sgml : 20170802 20170802213245 ACCESSION NUMBER: 0001572426-17-000028 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170731 FILED AS OF DATE: 20170802 DATE AS OF CHANGE: 20170802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HORN JURGEN CENTRAL INDEX KEY: 0001652810 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 171001910 MAIL ADDRESS: STREET 1: C/O NEXVET BIOPHARMA PLC STREET 2: NIBRT, FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK, CO. DUBLIN STATE: L2 ZIP: L2 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2017-07-31 1 0001618561 Nexvet Biopharma plc NVET 0001652810 HORN JURGEN C/O NEXVET BIOPHARMA PLC UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD TULLAMORE L2 R35 FR98 IRELAND 0 1 0 0 Chief Product Development Ofcr Ordinary Shares 2017-07-31 4 D 0 15750 6.72 D 0 D Option to purchase Ordinary Shares 5.10 2017-07-31 4 D 0 60000 1.62 D 2022-08-26 Ordinary Shares 60000 0 D Restricted Share Units .125 2017-07-31 4 D 0 47250 6.595 D 2021-07-01 Ordinary Shares 47250 0 D Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer (the "Acquisition") This option to purchase Ordinary Shares, which would have vested as to 12,000 shares on each of 9/30/17, 12/31/17, 3/31/18, 6/30/18, 9/30/18, 12/31/18, 3/31/19 and 6/30/19, was cancelled in the Acquisition in exchange for a cash payment equal to $97,200. This amount represents the difference between such exercise price per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on exercise of the option. This restricted share unit, which would have vested and become convertible as to 15,750 shares on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $311,613.75. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit. /s/ Jurgen Horn by Geraldine T. Farrell, Attorney-in-Fact 2017-07-31